The stock of Cytek Biosciences Inc. (NASDAQ:CTKB) increased by $0.07 on Friday to finish at $7.65, up 0.92 percent. The last five days have seen an average of 647,920 shares of common stock traded. 13 times new highs were reached in the current year, with a fall of -$2.56. The average number of shares traded over the last 20 days was 690,975, while the average volume over the last 50 days totaled 744,030.
CTKB stock dropped -14.04% since last month. On 08/25/23, the company’s shares reached a one-month low of $7.53. The stock touched a high of $15.90 on 02/10/23, after rallying from a low of $6.45 in 52 weeks. The price of CTKB stock has declined by -25.07% or -$2.56 this year, reaching a new high 13 times. Still, the stock price is down -51.89% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CTKB stock investors should be aware that Cytek Biosciences Inc. (CTKB) stock had its last reported insider trading activity 7 days ago on Aug 21. On Aug 21, Chief Technology Officer Yan Ming sold 20,000 shares at $8.07 each. This transaction resulted in the insider making $161,400. On Aug 07, Jiang Wenbin sold 20,000 shares at a price of US$9.04. After the transaction, the insider now owns 7,613,467 shares. Chief Technology Officer Yan Ming had earlier sold 20,000 shares on Jul 19 for $8.76 a share. The transaction was completed for $175,200.
Valuation Metrics
Beta for the stock is 0.50. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 5.89, the price-to-book (PB) ratio of 2.45.
Financial Health
For the three months ended June 29, Cytek Biosciences Inc.’s quick ratio was 6.70, while its current ratio was 7.90, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 60.00% percent. Cytek Biosciences Inc.’s EBITDA margin for the year ended June 29 was 2.74%, whereas its operating margin stood at -11.30% for the same period. Based on annual data, it had gross profit of $100.97 million and revenue of $164.04 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CTKB’s return on assets (ROA) during the last 12 months has been -1.20%. There was a -0.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -1.40%.
Earnings Surprise
According to Cytek Biosciences Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $49.16 million, while revenues rose by 18.31% to $37.09 million. It was predicted that Cytek Biosciences Inc.’s quarterly earnings would be -$0.03, but it ended up being $0.03. EBITDA was -$6.68 million for the quarter. At the end of Cytek Biosciences Inc.’s most recent quarter ended June 29, its liabilities totaled 100.88 million, while its total debt was $16.21 million. Equity owned by shareholders amounts to $136.36 million.
Technical Picture
Here’s a quick look at Cytek Biosciences Inc.’s (CTKB) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 24.82%, suggesting the stock is oversold, with a 34.31% historical volatility rate.
The stochastic %K and %D were 4.75% and 7.87% respectively, while the average true range (ATR) was 0.37. Based on the 14-day stochastic reading of 6.70%, the RSI (14) reading is 31.13%. On the 9-day MACD Oscillator, the stock is at -0.42, and the 14-day reading is at -0.75.
Analyst Ratings
In its analyst report released on July 19, 2023, Raymond James began covering Cytek Biosciences Inc. (NASDAQ: CTKB). The stock was rated as a Mkt perform by the brokerage firm. Analysts have assigned Cytek Biosciences Inc. (CTKB) an Overweight rating. CTKB is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is CTKB’s price target for the next 12 months?
The current consensus forecast for the stock is between $11.00 and $17.00, with a median target price of $14.00. In analyzing these forecasts, the average price target given by analysts for Cytek Biosciences Inc. (CTKB) is $14.00.
